GlassScriptPhysician profile
Joseph L Jackson
NPI 1366483356
$2,969.88
in general payments reported to CMS, 2019-2025
32 companies · $87.73 in 2025
The $87.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $444 · 2021: $701 · 2022: $562 · 2023: $302 · 2024: $187 · 2025: $87.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $420.54 | 2019-2024 | |
| Novo Nordisk INC | $335.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $300.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.91 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $143.51 | 2019-2023 | |
| Amgen INC. | $138.55 | 2019-2021 | |
| Lilly USA, LLC | $128.27 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $115.13 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $108.52 | 2019-2020 | |
| Amarin Pharma, INC. | $96.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.58 | 2021-2023 | Xifaxan, Trulance |
| Abbott Laboratories | $76.36 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $76.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $75.99 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $60.98 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $58.24 | 2021-2023 | Rexulti |
| Esperion Therapeutics, INC. | $52.22 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $47.64 | 2021 | |
| Antares Pharma, INC. | $46.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $25.69 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.11 | 2021 | |
| Daiichi Sankyo INC. | $21.00 | 2022 | |
| Genentech USA, INC. | $17.65 | 2020 | |
| Boston Scientific Corporation | $16.93 | 2020 | |
| Merck Sharp & Dohme LLC | $14.00 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.74 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $11.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.